Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib

Abstract

Background. A 57-year-old woman presented to the emergency department at a community hospital with a 2-month history of fatigue and right-sided flank and abdominal pain. Noncontrast CT of the abdomen and pelvis revealed a 9.1 cm right renal mass.

Investigations. Contrast CT of the chest, abdomen and pelvis, MRI of the abdomen and pelvis with gadolinium, radionuclide bone scan, lung nodule biopsy, complete blood count, comprehensive metabolic profile, and measurement of serum lactate dehydrogenase.

Diagnosis. Stage IV, T3bN0M1 clear cell renal cell carcinoma, with an associated tumor thrombus extending into the vena cava.

Management. The patient was treated with neoadjuvant sunitinib, which resulted in a marked response in the primary tumor and metastatic lesions as well as regression of the tumor thrombus well into the renal vein. Thus, laparoscopic radical nephrectomy was feasible and was achieved without hemorrhagic or wound healing complications. One month after surgery, she had evidence of disease progression in the lung and a periaortic lymph node. She was restarted on sunitinib with resultant disease stabilization, but discontinued the drug owing to toxicity. Eight months after cessation of sunitinib, she received a dendritic cell vaccine. She remains alive without evidence of disease progression 2 years after her diagnosis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Imaging of the patient's kidney before targeted therapy with a tyrosine kinase inhibitor.
Figure 2: Imaging of the patient's kidney after administration of sunitinib.

References

  1. Motzer, R. J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16–24 (2006).

    Article  CAS  Google Scholar 

  2. Rini, B. I. Tyrosine-kinase inhibitors in a presurgical setting. Presented at the American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, 2009 February 26–28, Orlando, FL, USA.

    Google Scholar 

  3. Thomas, A. A. et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518–523 (2009).

    Article  CAS  Google Scholar 

  4. Wood, C. G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res. 13, 697s–702s (2007).

    Article  Google Scholar 

  5. Escudier, B. et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280–1289 (2009).

    Article  CAS  Google Scholar 

  6. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    Article  CAS  Google Scholar 

  7. Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).

    Article  Google Scholar 

  8. Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700–9704 (1994).

    Article  CAS  Google Scholar 

  9. Choueiri, T. K. et al. von Hippel–Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 180, 860–865 (2008).

    Article  CAS  Google Scholar 

  10. Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530–2540 (1999).

    Article  CAS  Google Scholar 

  11. Mekhail, T. M. et al. Validation and extension of the Memorial Sloan–Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832–841 (2005).

    Article  Google Scholar 

  12. Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).

    Article  CAS  Google Scholar 

  13. Choueiri, T. K. et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110, 543–550 (2007).

    Article  CAS  Google Scholar 

  14. Kearney, G. P., Waters, W. B., Klein, L. A., Richie, J. P. & Gittes, R. F. Results of inferior vena cava resection for renal cell carcinoma. J. Urol. 125, 769–773 (1981).

    Article  CAS  Google Scholar 

  15. Libertino, J. A., Zinman, L. & Watkins, E. Jr. Long-term results of resection of renal cell cancer with extension into inferior vena cava. J. Urol. 137, 21–24 (1987).

    Article  CAS  Google Scholar 

  16. Neves, R. J. & Zincke, H. Surgical treatment of renal cancer with vena cava extension. Br. J. Urol. 59, 390–395 (1987).

    Article  CAS  Google Scholar 

  17. Skinner, D. G., Pritchett, T. R., Lieskovsky, G., Boyd, S. D. & Stiles, Q. R. Vena caval involvement by renal cell carcinoma: surgical resection provides meaningful long-term survival. Ann. Surg. 210, 387–392 (1989).

    Article  CAS  Google Scholar 

  18. Yagoda, A., Petrylak, D. & Thompson, S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am. 20, 303–321 (1993).

    CAS  PubMed  Google Scholar 

  19. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688–696 (1995).

    Article  CAS  Google Scholar 

  20. Fyfe, G. A. et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 14, 2410–2411 (1996).

    Article  CAS  Google Scholar 

  21. McDermott, D. F. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133–141 (2005).

    Article  CAS  Google Scholar 

  22. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).

    Article  CAS  Google Scholar 

  23. Figlin, R. A. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Presented at the American Society of Clinical Oncology 2008 annual meeting, 2008 May 30–June 3, Chicago, IL, USA.

    Book  Google Scholar 

  24. Motzer, R. J. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516–2524 (2006).

    Article  CAS  Google Scholar 

  25. Flanigan, R. C. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071–1076 (2004).

    Article  Google Scholar 

  26. Flanigan, R. C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655–1659 (2001).

    Article  CAS  Google Scholar 

  27. Mickisch, G. H., Garin, A., van Poppel, H., de Prijck, L. & Sylvester, R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001).

    Article  CAS  Google Scholar 

  28. Walther, M. M. et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 42, 250–257 (1993).

    Article  CAS  Google Scholar 

  29. Biswas, S., Kelly, J. & Eisen, T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 14, 52–59 (2009).

    Article  Google Scholar 

  30. Rini, B. I. & Campbell, S. C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J. Urol. 177, 1978–1984 (2007).

    Article  CAS  Google Scholar 

  31. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).

    Google Scholar 

  32. Nexavar® (Sorafenib) package insert (Bayer Pharmaceuticals, 2007).

  33. Avastin® (Bevacizumab) package insert (Genentech, 2008).

  34. Gordon, M. S. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843–850 (2001).

    Article  CAS  Google Scholar 

  35. Sutent® (Sunitinib maleate) package insert (Pfizer, 2007).

  36. Amin, C. et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72, 864–868 (2008).

    Article  Google Scholar 

  37. Margulis, V. et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180, 94–98 (2008).

    Article  Google Scholar 

  38. Neill, M. G., Wei, A. C. & Jewett, M. A. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy. Urology 70, 178.e9–e11 (2007).

    Article  Google Scholar 

  39. Scappaticci, F. A. et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 91, 173–180 (2005).

    Article  CAS  Google Scholar 

  40. Finelli, A. et al. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int. 94, 291–294 (2004).

    Article  Google Scholar 

  41. Walther, M. M., Lyne, J. C., Libutti, S. K. & Linehan, W. M. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 53, 496–501 (1999).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Benjamin I. Chung.

Ethics declarations

Competing interests

S. Srinivas declares that he has received speakers' bureau honoraria from Pfizer. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harshman, L., Srinivas, S., Kamaya, A. et al. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 6, 338–343 (2009). https://doi.org/10.1038/nrurol.2009.84

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2009.84

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing